ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100's Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

(marketscreener.com) Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative diseases, such as amyotrophic lateral sclerosis This study showed that NLRP3 inhibition alone was inadequate to address CNS inflammation in a mouse model of ALSZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit up...https://www.marketscreener.com/quote/stock/ZYVERSA-THERAPEUTICS-INC-148115421/news/ZyVersa-Therapeutics-Announces-Research-Published-in-Frontiers-in-Immunology-Reinforcing-IC-100-s-Ra-44822084/?utm_medium=RSS&utm_content=20230912